VAXCYTE, INC. (PCVX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -1.17B USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 1.03B USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-1.17B | (m) | (m) | $1.03B | (m) | (m) |
| 2026-03-31 | $-1.09B | (m) | (m) | $958.95M | (m) | (m) |
| 2025-12-31 | $-923.67M | (m) | (m) | $794.31M | (m) | (m) |
| 2025-09-30 | $-811.56M | (m) | (m) | $685.86M | (m) | (m) |
| 2025-06-30 | $-709.11M | (m) | (m) | $592.86M | (m) | (m) |
| 2025-03-31 | $-635.87M | (m) | (m) | $530.19M | (m) | (m) |
| 2024-12-31 | $-569.55M | (m) | (m) | $476.64M | (m) | (m) |
| 2024-09-30 | $-604.05M | (m) | (m) | $447.18M | (m) | (m) |
| 2024-06-30 | $-577.16M | (m) | (m) | $427.66M | (m) | (m) |
| 2024-03-31 | $-511.32M | (m) | (m) | $368.85M | (m) | (m) |
| 2023-12-31 | $-468.04M | (m) | (m) | $332.34M | (m) | (m) |
| 2023-09-30 | $-357.94M | (m) | (m) | $279.82M | (m) | (m) |
| 2023-06-30 | $-303.49M | (m) | (m) | $230.07M | (m) | (m) |
| 2023-03-31 | $-264.23M | (m) | (m) | $195.85M | (m) | (m) |
| 2022-12-31 | $-232.26M | (m) | (m) | $169.45M | (m) | (m) |
| 2022-09-30 | $-175.53M | (m) | (m) | $140.90M | (m) | (m) |
| 2022-06-30 | $-143.90M | (m) | (m) | $113.65M | (m) | (m) |
| 2022-03-31 | $-119.75M | (m) | (m) | $92.83M | (m) | (m) |
| 2021-12-31 | $-103.67M | (m) | (m) | $78.41M | (m) | (m) |
| 2021-09-30 | $-93.28M | (m) | (m) | $70.00M | (m) | (m) |
| 2021-06-30 | $-87.63M | (m) | (m) | $65.98M | (m) | (m) |
| 2021-03-31 | $-85.13M | (m) | (m) | $66.51M | (m) | (m) |
| 2020-12-31 | $-89.58M | (m) | (m) | $73.56M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-67.81M | (m) | (m) | $57.29M | (m) | (m) |
| 2019-12-31 | $-54.15M | (m) | (m) | $45.61M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-35.53M | (m) | (m) | $30.14M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |